Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, hosted by Drs. Rahul and Rohit Gosain, aims to bridge the gap between academic cancer centers and community oncology. It features short interviews with leading researchers and clinicians, discussing practice-changing data in hematology and oncology. The podcast covers FDA approvals, conference highlights, and treatment algorithms for common cancers like breast, prostate, lung, and GI cancers. It is intended for physicians, nurses, and advanced practice providers involved in cancer care.
Episodes
ASCO 2026 Breast Highlights: OPTIMA, lidERA, VIKTORIA-1, KEYNOTE-522, ASCENT-03/04, TROPION-Breast02
In this ASCO 2026 Highlights discussion we dived into the latest advancements in breast cancer space. In this episode, we welcomed back Dr. Hope Rugo to discuss key studies that are shaping the future of breast cancer treatment.
Episode Highlights:
OPTIMA: Discover how the Prosigna genomic assay could change the approach to adjuvant chemotherapy in hormone receptor-positive breast cancer.
lidER
EHA2026 Multiple Myeloma Highlights: CEPHEUS, MajesTEC-3, MajesTEC-9, MonumenTAL-3, SUCCESSOR-2
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.
Join us as we dived into:
The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
Insights on the efficacy of teclistama
Evolving Treatment Landscape of Multiple Myeloma: Bispecifics, CAR T, and CELMoDs
We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.
Discover the current treatment algor
Challenging Cases - Treatment of Renal Cell Carcinoma (RCC): Dr. Pedro Barata
Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.
We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest f
ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)
Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.
In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent
To hold or NOT to hold Systemic Therapy with Radiation: Dr. Nina Sanford
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.
Join us as we explore:
The framework for balancing systemic therapy with different types of radiation, including SBRT,
ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN
Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.
We discussed key studies:
EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes.
FIGHT-302 in
RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin
In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.
We discussed:
The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients.
The trial design and key findings of the RASolute 302 study, high
ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg
Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma.
Join us as we discuss:
Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers?
Amivantamab
Challenging Cases - Treatment of Common EGFR Mutations in Metastatic Non-Small Cell Lung Cancer
In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases.
The first case featured a 54-year-old gentleman with active tobacco
Lung Cancer ASCO 2026 Highlights: LIBRETTO-432, CROWN Update, CHRYSALIS-2, HARMONi-6
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026.
We dived into four key studies that could change clinical practice:
LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implica
RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer
Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.
We were joined by e
ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026.
We dived into key studies and recent FDA approvals, including:
The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer.
Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina.
Join us as we explore two challenging cases:
Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrange
Challenging Cases in Chronic Myeloid Leukemia (CML): Drs. Fadi Haddad & Gaby Hobbs
Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of chronic myeloid leukemia (CML) through two challenging case studies. Joined by CML experts Dr. Fadi Haddad from MD Anderson Cancer Center and Dr. Gaby Hobbs from Massachusetts General Hospital,
we talked about:
The initial workup for diagnosing CML, including the importance of CBC, bone marrow biopsy,
Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafe
Treating BRAF V600E Mutated Non-Small Cell Lung Cancer (NSCLC) with Dr. Gregory Riely
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of BRAF V600E-driven non-small cell lung cancer (NSCLC) with our guest Dr. Gregory Riely, a thoracic medical oncologist from Memorial Sloan Kettering Cancer Center.
Join us as we explore:
The prevalence of BRAF V600E mutations in NSCLC and how they compare to other oncogenic drivers.
The latest treatment opt
Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists.
Key topics included:
Overview of
Managing Toxicities of EGFR Inhibitors in Lung Cancer – Drs. Azam Farooqui & Joshua Sabari
In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab an
How to Treat Metastatic NSCLC with Targetable Mutations – Treatment Algorithm with Dr. Eric Singhi
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting.
We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including:
Common EGFR mutations and the benefits of combination th
How to Treat Metastatic NSCLC W/O Targeted Mutations – Treatment Algorithm with Dr. Christine Garcia
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings.
We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored t
How to Treat Localized Non-Small Cell Lung cancer – Treatment Algorithm with Dr. Sanjay Popat
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain dive deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with curative intent. Joined by leading thoracic medical oncologist Dr. Sanjay Popat from London, they discussed the critical role of next-generation sequencing (NGS) in treatment planning, the importan
How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, to discuss the current treatment algorithms for small cell lung cancer (SCLC).
We dived deep into the aggressive nature of SCLC and the meaningful advances in treatment over the past few years. Key topics included:
The role of surgery and
Managing Toxicities of Colorectal Cancer Drugs / Systemic Therapy – Dr. Rona Yaeger
Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer.
Episode Highlights:
• Overview of 5-FU and capecitabine,
BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy
Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment.
Join us as we discussed:
The prevalence and outcomes associated with BRAF V600E mutations
Recent advances in treatment options, including the BREAKWATER study
The significa
How to Treat Colorectal Cancer – Treatment Algorithm with Dr. Smitha Krishnamurthi
In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings.
Key topics discussed included:
How to Treat Pancreatic Cancer – Treatment Algorithm with Dr. Shubham Pant
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center.
Join us as we explored:
The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings.
The importance of germline testing and next-generation sequencing (NGS) in guidin
How to Treat Biliary Tract Cancer – Treatment Algorithm with Dr. Suneel Kamath
In this episode of the Oncology Brothers, we welcomed Dr. Suneel Kamath from the Cleveland Clinic to discuss the complex landscape of biliary tract cancer. While this cancer type is not the most common, it carries a poor prognosis, making it crucial for oncologists to stay informed about the latest treatment options.
Join us as we explored:
The role of surgery and adjuvant chemotherapy in early
How to Treat Cancer of Unknown Primary (CUP) Origin – Drs. Harry Fuentes & Thor Halfdanarson
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of Cancer of Unknown Primary (CUP). Joined by Dr. Harry Fuentes Bayne and Dr. Thor Halfdanarson from the Mayo Clinic, they discussed the current standard of care, diagnostic workup, and treatment options for this challenging condition.
Key topics included:
Initial diagnostic approaches for CUP, including imagi
How to Treat Bladder Cancer – Drs. Stephanie Berg (Medical Oncologist) & Joshua Meeks (Urologist)
Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving treatment algorithms for bladder cancer following the latest data presented at GU ASCO 2026.
Join us as we explore:
The role of immunotherapy in non-muscle invasive bladder cancer, highlighting the recent positive trials: CREST with Sasanlimab and POTOMAC with Durvalumab.
Insights on the current standard of ca
Open Evidence as an Artificial Intelligence (AI) Tool in the World of Medicine
In this episode of the Oncology Brothers podcast, we dived into the transformative role of artificial intelligence (AI) in oncology and medical practice. Joined by Dr. Travis Zack, Chief Medical Officer of Open Evidence, we explored how large language models (LLMs) are revolutionizing the way clinicians access and utilize medical information.
Key topics included:
The rapid evolution of AI in he
How to Treat Renal Cell Carcinoma (RCC) in 2026 – Dr. Katy Beckermann
Welcome back to the Oncology Brothers podcast! In this episode, we discussed current treatment landscape and updates from GU ASCO 2026, with focus on kidney cancer.
We were joined by Dr. Katy Beckermann, a medical oncologist from Tennessee Oncology, to discuss:
The current standard of care for renal cell carcinoma (RCC), including adjuvant treatment options post-surgery.
The implications of the
Evolving Treatment Landscape of HER2+ Upper GI Cancer
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer.
Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We di
How to Treat Prostate Cancer Localized to Advanced Settings - Dr. Scott Tagawa
Welcome to the Oncology Brothers podcast! In this episode, we discussed the current treatment landscape for prostate cancer, featuring special guest Dr. Scott Tagawa, a GU Medical Oncologist from Weill Cornell Medicine.
Join us as we explored:
The current standard of care for localized prostate cancer, including active surveillance, surgery, and radiation.
The significance of ADT and abirateron
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HE
GU ASCO 2026 Highlights – CREST, POTOMAC, EV-304/KEYNOTE-B15, LITESPARK-011/022, CAPITELLO-281
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer.
Key topics discussed included:
CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ra
Clinical Insights: Evolving Landscape of Bladder Cancer After GU ASCO 2026
We had the opportunity to dive into the evolving landscape of bladder cancer treatment in this insightful podcast episode at GU ASCO 2026. Featuring expert guests Dr. Chad Reichard, Dr. Shilpa Gupta, Dr. Matt Galsky, and Dr. Sia Daneshmand, the discussion covered the latest FDA-approved options for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), and exciting d
Teclistamab-Daratumumab FDA Approval of MajesTEC-3 for R/R Multiple Myeloma (MM): Dr. Luciano Costa
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma.
Key topics discussed included:
The i
Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina
Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for
Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer
Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).
Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metast
HER2+ Breast Cancer Treatment Algorithm: Dr. Virginia Kaklamani
In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies.
Key
Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin Kalinsky
In this episode of the Oncology Brothers podcast we navigated the rapidly evolving treatment landscape of Metastatic Hormone Receptor-Positive Breast Cancer. We were joined by Dr. Kevin Kalinsky, Director of the Breast Cancer Program at the Winship Cancer Institute, Emory University, to discuss the implications of new targeted therapies, optimal sequencing strategies, and practical toxicity manage
Early Stage Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Erica Mayer
In this episode of the Oncology Brothers podcast, hosts Rahul and Rohit Gosain dived deep into the evolving landscape of breast cancer treatment algorithms, focusing on early and locally advanced hormone receptor-positive breast cancer. Joined by Dr. Erica Mayer, a breast medical oncologist at the Dana-Farber Cancer Institute.
The discussion covered:
The role of chemotherapy in early-stage hor
Current & Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong
In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of rev
Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months
Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver
In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option.
Episode Highlights:
Overview of therapy-related AML and its increasing prevalence due to advancement
Head & Neck Cancers Treatment Landscape & Algorithm – Dr. Fangdi Sun
In this episode of the Oncology Brothers podcast, we dived into the current treatment landscape for head and neck cancer. We welcomed Dr. Fangdi Sun, a head and neck medical oncologist from Stanford University, to discuss key topics including:
The importance of initial workup and the role of biomarkers, including HPV and EBV testing.
Treatment paradigm for early-stage and locally advanced head an
FDA Approval of Daratumumab in High Risk Smoldering Myeloma: AQUILA by Dr. Vincent Rajkumar
In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of daratumumab for high-risk smoldering myeloma, based on the groundbreaking AQUILA study. We were joined by Dr. Vincent Rajkumar, a world-renowned myeloma specialist, who provided valuable insights into the complexities of smoldering myeloma, its risk stratification, and the implications of early intervention.
ASH 2025 Multiple Myeloma Highlights – AQUILA, COBRA, TecLILLE, MajesTEC-3: Dr. Ben Derman
Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.
In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-hea
GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff
We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in
ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose
In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).
Episode Highlights:
EPCORE FL-1: the approval of Epcoritamab in combination with Rituxim
ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes
In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 inductio
HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein
Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive
Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky
In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC).
Join us as we discussed:
The RJBC 1501 study, which
Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles
Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study.
We are t
Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo
Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer.
Join us as we discussed:
The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies
Insights into second-line treatment options, including the VIKTORIA-1, evERA,
Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE
In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.
Join us as we dive into three key abstracts:
ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the i
Advancements and Challenges in Metastatic Colorectal Cancer Treatment
In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi.
Key topics included:
The importance of next-generation sequencin
Clinical Implications of Testing HER2 and Targeted Therapies Approved - Dr. Komal Jhaveri
In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.
Key topics include:
The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impac
Toxicity Management of HER2+ Treatment Options in Upper GI Cancers – Drs. Geoffrey Ku & Shruti Patel
Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University.
Building on their previous discussion of upper GI treatment algori
Current Treatment Landscape of Advanced Gastric/Esophageal/GEJ Adenocarcinoma – Dr. Rutika Mehta
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease.
Episode Highlights:
Overview of recent advancements in the treatment
Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands
In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V).
We explored the side
Managing Toxicities of PI3K & AKT Inhibitors in Breast Cancer – Drs. Emily Gallagher & Neil Iyengar
Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer.
We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and ga
Challenging Cases of Iron Abnormalities, Anemia or Iron Overload - Dr. Marina Beltrami
Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:
Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and
FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall respon
Challenging Cases in Second Line & Beyond Renal Cell Carcinoma (RCC) - Dr. David Braun
In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases.
We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) th
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janj
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic s
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder c
FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang
In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).
We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, ef
Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez
Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients.
Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:
T
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).
Join us as we delve into:
An overview of the different generations of TKIs, incl
Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer.
Episode Highlights:
MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary app
GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101
In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice.
Episode Highlighted:
ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studi
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer.
We dived deep into the most impactful studies, including:
MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has over
Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer.
Join us as we discuss:
The importance of surgical staging and debulking surgery in ovarian cancer treatment.
The role of neoadjuvant chemotherapy and the significance of germlin
GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011
In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care.
Episode Highlights:
PSMAddition: Explore the b
Challenging Cases with Metastatic EGFR Mutated Non-Small Cell Lung Cancer with Dr. Eric Singhi
Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC).
We explored the latest treatment options, including:
Osimertinib
Amivantamab plus Lazertinib (based
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and pa
Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).
Join us as we dive into the essential aspects of CML treatment, including:
The importance of initial workup and bone marrow biopsy in diagnosing CML.
Risk stratification and the selection of first-lin
Recommended
Guiding God‘s Girls
The Clinic Marketing Podcast | Local SEO & Healthcare Online Marketing Tips for Clinic Owners & Wellness Providers
Money Magnet Mode | Daily Affirmations That Work,
DJ BURST 305
The No BS Spiritual Book Club with Sandie Sedgbeer
The Daily
Doctor Zhivago Slow Read
Conspiracy Files with Paige Carter
This Past Weekend w/ Theo Von
The Theory of Psychoanalysis - Carl Jung
A Life Engineered
پادکست بهزاد بلور | Behzad Bolour's Podcast
